IDEXX Laboratories (IDXX) Price Target Hiked to $580 at Leerink Partners

Abdul Rahman

Tue, Jun 17, 2025, 2:24 AM 1 min read

IDEXX Laboratories Inc. (NASDAQ:IDXX) is among the 12 best healthcare stocks. On June 11, Leerink Partners analyst Daniel Clark reiterated an Outperform rating on the stock. However, the analyst increased his stock price target to $580 from $515.

A veterinarian in a veterinary clinic examining a companion animal.

According to the analyst IDEXX Laboratories has evolved to become the largest player in the veterinarian space. It enjoys a dominant market share and robust growth profile. He expects the company’s offerings to play an integral part in the vet office in terms of workflow and profitability.

While some of IDEXX Laboratories’ revenue growth depends on visit volumes beyond its control, the analyst remains confident in the long-term outlook thanks to consistently high levels of pet ownership. Owners increasing spending on pet wellness and overall health are a welcome for the company.

IDEXX Laboratories Inc. (NASDAQ:IDXX) is a healthcare company that develops, manufactures, and distributes products and services for veterinary diagnostics, livestock and poultry diagnostics, water testing, dairy testing, and human medical diagnostics.

While we acknowledge the potential of IDXX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Stocks Analysts Are Upgrading Today and 13 Best AI Stocks to Buy Under $10.

Disclosure: None.